Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1997 Aug;43:1395–1404.

Treatment options for benign prostatic hyperplasia.

A J Portis 1, D R Mador 1
PMCID: PMC2255402  PMID: 9266125

Abstract

OBJECTIVE: To examine current treatment options for benign prostatic hyperplasia with emphasis on randomized, clinical trials and our current management approach. QUALITY OF EVIDENCE: Benign prostatic hyperplasia remains difficult to define clinically or measure objectively. As a result, research has been fairly weak. With newer treatments, however, more definitive studies have been reported. MAIN FINDINGS: Transurethral resection of the prostate remains the criterion standard for severe disease. Watchful waiting, medical management, or early surgical intervention are all valid options for moderate disease and should be tailored to the characteristics and desires of individual patients. Recent minimally invasive surgical techniques, such as microwave and laser surgery, have not yet achieved the quality of evidence to be generally recommended. CONCLUSIONS: Management of benign prostatic hyperplasia should be individualized to patients' circumstances and personal choices.

Full text

PDF
1398

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry M. J. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990 Aug;17(3):495–507. [PubMed] [Google Scholar]
  2. Barry M. J., Fowler F. J., Jr, O'Leary M. P., Bruskewitz R. C., Holtgrewe H. L., Mebust W. K., Cockett A. T. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549–1564. doi: 10.1016/s0022-5347(17)36966-5. [DOI] [PubMed] [Google Scholar]
  3. Bartsch G., Müller H. R., Oberholzer M., Rohr H. P. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979 Oct;122(4):487–491. doi: 10.1016/s0022-5347(17)56476-9. [DOI] [PubMed] [Google Scholar]
  4. Bdesha A. S., Bunce C. J., Snell M. E., Witherow R. O. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol. 1994 Aug;152(2 Pt 1):453–458. doi: 10.1016/s0022-5347(17)32761-1. [DOI] [PubMed] [Google Scholar]
  5. Berry S. J., Coffey D. S., Walsh P. C., Ewing L. L. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474–479. doi: 10.1016/s0022-5347(17)49698-4. [DOI] [PubMed] [Google Scholar]
  6. Bihrle R., Foster R. S., Sanghvi N. T., Donohue J. P., Hood P. J. High intensity focused ultrasound for the treatment of benign prostatic hyperplasia: early United States clinical experience. J Urol. 1994 May;151(5):1271–1275. doi: 10.1016/s0022-5347(17)35230-8. [DOI] [PubMed] [Google Scholar]
  7. Bosch J. L., Hop W. C., Kirkels W. J., Schröder F. H. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol. 1995 May;75(5):622–630. doi: 10.1111/j.1464-410x.1995.tb07421.x. [DOI] [PubMed] [Google Scholar]
  8. Boyarsky S., Jones G., Paulson D. F., Prout G. R., Jr A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg. 1976;68:29–32. [PubMed] [Google Scholar]
  9. Caine M., Pfau A., Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976 Aug;48(4):255–263. doi: 10.1111/j.1464-410x.1976.tb03013.x. [DOI] [PubMed] [Google Scholar]
  10. Christensen M. M., Aagaard J., Madsen P. O. Transurethral resection versus transurethral incision of the prostate. A prospective randomized study. Urol Clin North Am. 1990 Aug;17(3):621–630. [PubMed] [Google Scholar]
  11. Cowles R. S., 3rd, Kabalin J. N., Childs S., Lepor H., Dixon C., Stein B., Zabbo A. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology. 1995 Aug;46(2):155–160. doi: 10.1016/s0090-4295(99)80185-x. [DOI] [PubMed] [Google Scholar]
  12. Dahlstrand C., Geirsson G., Fall M., Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for benign prostatic hyperplasia: preliminary results of a randomized study. Eur Urol. 1993;23(2):292–298. doi: 10.1159/000474615. [DOI] [PubMed] [Google Scholar]
  13. Geller J., Kirchenbaum A., Lepor H., Levine A. C. Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. J Clin Endocrinol Metab. 1995 Mar;80(3):745–747. doi: 10.1210/jcem.80.3.7533770. [DOI] [PubMed] [Google Scholar]
  14. Gerber G. S. Lasers in the treatment of benign prostatic hyperplasia. Urology. 1995 Feb;45(2):193–199. doi: 10.1016/0090-4295(95)80004-2. [DOI] [PubMed] [Google Scholar]
  15. Girman C. J., Jacobsen S. J., Guess H. A., Oesterling J. E., Chute C. G., Panser L. A., Lieber M. M. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995 May;153(5):1510–1515. doi: 10.1016/s0022-5347(01)67448-2. [DOI] [PubMed] [Google Scholar]
  16. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191. doi: 10.1056/NEJM199210223271701. [DOI] [PubMed] [Google Scholar]
  17. Holtgrewe H. L., Mebust W. K., Dowd J. B., Cockett A. T., Peters P. C., Proctor C. Transurethral prostatectomy: practice aspects of the dominant operation in American urology. J Urol. 1989 Feb;141(2):248–253. doi: 10.1016/s0022-5347(17)40732-4. [DOI] [PubMed] [Google Scholar]
  18. Jønler M., Bruskewitz R. C. Transurethral incision of the prostate for the treatment of benign prostatic hyperplasia. Semin Urol. 1994 Aug;12(3):156–160. [PubMed] [Google Scholar]
  19. Kaplan S. A., Chiou R. K., Morton W. J., Katz P. G. Long-term experience utilizing a new balloon expandable prostatic endoprosthesis: the Titan stent. North American Titan Stent Study Group. Urology. 1995 Feb;45(2):234–240. doi: 10.1016/0090-4295(95)80011-5. [DOI] [PubMed] [Google Scholar]
  20. Kaplan S. A., Te A. E. Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology. 1995 Apr;45(4):566–572. doi: 10.1016/S0090-4295(99)80044-2. [DOI] [PubMed] [Google Scholar]
  21. Lepor H. Alpha 1-adrenoceptor selectivity: clinical or theoretical benefit? Br J Urol. 1995 Jul;76 (Suppl 1):57–61. [PubMed] [Google Scholar]
  22. Lepor H., Auerbach S., Puras-Baez A., Narayan P., Soloway M., Lowe F., Moon T., Leifer G., Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 1992 Nov;148(5):1467–1474. doi: 10.1016/s0022-5347(17)36941-0. [DOI] [PubMed] [Google Scholar]
  23. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology. 1995 Mar;45(3):406–413. doi: 10.1016/s0090-4295(99)80008-9. [DOI] [PubMed] [Google Scholar]
  24. Matzkin H. Hyperthermia as a treatment modality in benign prostatic hyperplasia. Urology. 1994 Feb;43(2 Suppl):17–20. doi: 10.1016/0090-4295(94)90213-5. [DOI] [PubMed] [Google Scholar]
  25. McCullough D. L., Roth R. A., Babayan R. K., Gordon J. O., Reese J. H., Crawford E. D., Fuselier H. A., Smith J. A., Murchison R. J., Kaye K. W. Transurethral ultrasound-guided laser-induced prostatectomy: National Human Cooperative Study results. J Urol. 1993 Nov;150(5 Pt 2):1607–1611. doi: 10.1016/s0022-5347(17)35855-x. [DOI] [PubMed] [Google Scholar]
  26. Mebust W. K., Holtgrewe H. L., Cockett A. T., Peters P. C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989 Feb;141(2):243–247. doi: 10.1016/s0022-5347(17)40731-2. [DOI] [PubMed] [Google Scholar]
  27. Meyhoff H. H., Nordling J., Hald T. Urodynamic evaluation of transurethral versus transvesical prostatectomy. A randomized study. Scand J Urol Nephrol. 1984;18(1):27–35. doi: 10.3109/00365598409182160. [DOI] [PubMed] [Google Scholar]
  28. Meyhoff H. H., Nordling J. Long term results of transurethral and transvesical prostatectomy. A randomized study. Scand J Urol Nephrol. 1986;20(1):27–33. doi: 10.3109/00365598609024476. [DOI] [PubMed] [Google Scholar]
  29. Oesterling J. E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options. N Engl J Med. 1995 Jan 12;332(2):99–109. doi: 10.1056/NEJM199501123320207. [DOI] [PubMed] [Google Scholar]
  30. Oesterling J. E. Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology. 1994 Feb;43(2 Suppl):7–16. doi: 10.1016/0090-4295(94)90212-7. [DOI] [PubMed] [Google Scholar]
  31. Oesterling J. E., Kaplan S. A., Epstein H. B., Defalco A. J., Reddy P. K., Chancellor M. B. The North American experience with the UroLume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. The North American UroLume Study Group. Urology. 1994 Sep;44(3):353–362. doi: 10.1016/s0090-4295(94)80093-6. [DOI] [PubMed] [Google Scholar]
  32. Orandi A. Transurethral incision of prostate compared with transurethral resection of prostate in 132 matching cases. J Urol. 1987 Oct;138(4):810–815. doi: 10.1016/s0022-5347(17)43382-9. [DOI] [PubMed] [Google Scholar]
  33. Orandi A. Transurethral incision of the prostate. J Urol. 1973 Aug;110(2):229–231. doi: 10.1016/s0022-5347(17)60172-1. [DOI] [PubMed] [Google Scholar]
  34. Perlmutter A. P., Verdi J., Watson G. M. Prostatic heat treatments for urinary outflow obstruction. J Urol. 1993 Nov;150(5 Pt 2):1603–1606. doi: 10.1016/s0022-5347(17)35854-8. [DOI] [PubMed] [Google Scholar]
  35. Rittmaster R. S. Finasteride. N Engl J Med. 1994 Jan 13;330(2):120–125. doi: 10.1056/NEJM199401133300208. [DOI] [PubMed] [Google Scholar]
  36. Roos N. P., Ramsey E. W. A population-based study of prostatectomy: outcomes associated with differing surgical approaches. J Urol. 1987 Jun;137(6):1184–1188. doi: 10.1016/s0022-5347(17)44442-9. [DOI] [PubMed] [Google Scholar]
  37. Stamey T. A. Making the most out of six systematic sextant biopsies. Urology. 1995 Jan;45(1):2–12. doi: 10.1016/s0090-4295(95)96168-2. [DOI] [PubMed] [Google Scholar]
  38. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994 Mar;43(3):284–294. doi: 10.1016/0090-4295(94)90068-x. [DOI] [PubMed] [Google Scholar]
  39. Wasson J. H., Reda D. J., Bruskewitz R. C., Elinson J., Keller A. M., Henderson W. G. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995 Jan 12;332(2):75–79. doi: 10.1056/NEJM199501123320202. [DOI] [PubMed] [Google Scholar]
  40. Wilson D. E., Jirsch D. W., Mador D. R., Halliwell G. E., Raiwet C. J., Grace M. G., Predy G. N., Redfern L. E. Caremap management for postoperative prostatectomy care at home: a comparative study. Can J Surg. 1997 Feb;40(1):39–43. [PMC free article] [PubMed] [Google Scholar]
  41. Yerushalmi A., Servadio C., Leib Z., Fishelovitz Y., Rokowsky E., Stein J. A. Local hyperthermia for treatment of carcinoma of the prostate: a preliminary report. Prostate. 1982;3(6):623–630. doi: 10.1002/pros.2990030612. [DOI] [PubMed] [Google Scholar]
  42. de la Rosette J. J., de Wildt M. J., Alivizatos G., Froeling F. M., Debruyne F. M. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology. 1994 Jul;44(1):58–63. doi: 10.1016/s0090-4295(94)80010-3. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES